MedPath

Denali Therapeutics

🇺🇸United States
Ownership
-
Employees
445
Market Cap
-
Website
Introduction

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Clinical Trials

41

Active:17
Completed:14

Trial Phases

2 Phases

Phase 1:30
Phase 2:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials

Phase 1
30 (85.7%)
Phase 2
5 (14.3%)

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Phase 2
Recruiting
Conditions
Parkinson Disease
Interventions
Drug: BIIB122 225 mg
Other: BIIB122-Matching Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-06-03
Lead Sponsor
Denali Therapeutics Inc.
Target Recruit Count
50
Registration Number
NCT06602193
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 12 locations

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2024-02-28
Last Posted Date
2024-06-20
Lead Sponsor
Denali Therapeutics Inc.
Target Recruit Count
7
Registration Number
NCT06281158
Locations
🇺🇸

Clinical Site, Madison, Wisconsin, United States

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Phase 1
Recruiting
Conditions
Mucopolysaccharidosis Type IIIA
Interventions
First Posted Date
2023-12-26
Last Posted Date
2025-07-22
Lead Sponsor
Denali Therapeutics Inc.
Target Recruit Count
26
Registration Number
NCT06181136
Locations
🇺🇸

Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, United States

🇺🇸

UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

🇺🇸

University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States

and more 1 locations

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Phase 2
Conditions
Mucopolysaccharidosis II
Interventions
First Posted Date
2023-10-10
Last Posted Date
2025-06-22
Lead Sponsor
Denali Therapeutics Inc.
Target Recruit Count
99
Registration Number
NCT06075537
Locations
🇨🇦

University of Alberta - Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada

🇺🇸

UNC Children's Research Institute, Chapel Hill, North Carolina, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 11 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participant
Interventions
Drug: Placebo
First Posted Date
2022-07-08
Last Posted Date
2023-08-16
Lead Sponsor
Denali Therapeutics Inc.
Target Recruit Count
47
Registration Number
NCT05450549
Locations
🇳🇱

Centre for Human Drug Research (CHDR), Leiden, South Holland, Netherlands

  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.